As compared to the non-tTMB high expression group, which had an ORR of 6% (95% confidence interval, CI: 5–8%), the results of the tTMB high expression group showed an ORR of 29% (95% CI: 21–39%), indicating a stronger tumor response to pembrolizumab. Here, TMEM200B is linked to neoplasm.